首页> 外文期刊>Journal of vascular surgery >Intrathoracic subclavian artery aneurysm repair in the thoracic endovascular aortic repair era
【24h】

Intrathoracic subclavian artery aneurysm repair in the thoracic endovascular aortic repair era

机译:胸腔内主动脉修复时代的胸锁骨下动脉瘤修复

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: Intrathoracic subclavian artery aneurysms (SAAs) are rare aneurysms that often occur in association with congenital aortic arch anomalies and/or concomitant thoracic aortic pathology. The advent of thoracic endovascular aortic repair (TEVAR) methods may complement or replace conventional open SAA repair. Herein, we describe our experience with SAA repair in the TEVAR era. Methods: A retrospective review was performed of all intrathoracic SAAs repaired at a single institution since United States Food and Drug Administration approval of TEVAR in 2005. Results: Nineteen patients underwent 20 operations to repair 22 (13 native, nine aberrant) SAAs with an intrathoracic component. Mean SAA diameter was 3.1 cm (range, 1.6-6.0 cm). Mean patient age was 57 years (range, 24-80 years). Twenty-one percent (n = 4) of patients had a connective tissue disorder (two Loeys-Dietz, two Marfan). Thirty-six percent (n = 8) of SAAs were repaired by open techniques and 64% (n = 14) via a TEVAR-based approach. All TEVAR cases required proximal landing zone in the aortic arch (zone 0-2), and revascularization of at least one arch vessel was required in 83% (10/12) of patients. Concomitant repair of associated aortic pathology was performed in 50% (n = 10) of operations. Thirty-day/in-hospital rates of death, stroke, and permanent paraplegia/paraparesis were 5% (n = 1), 5% (n = 1), and 0%, respectively. Over mean (standard deviation) follow-up of 24 (21) months, 16% (n = 3) of patients required reintervention for subclavian artery bypass graft revision (n = 2) or type II endoleak (n = 1). Conclusions: This is the largest single-institution series to date of TEVAR for SAA repair. Modern endovascular techniques expand SAA repair options with excellent results. The majority of SAAs and nearly all aberrant SAAs (Kommerell's diverticulum) can now be repaired using a TEVAR-based approach without the need for sternotomy or thoracotomy.
机译:目的:胸腔锁骨下动脉瘤(SAA)是一种罕见的动脉瘤,常与先天性主动脉弓畸形和/或伴发胸主动脉病变有关。胸腔内血管主动脉修复(TEVAR)方法的出现可能补充或替代了常规的开放式SAA修复。在此,我们描述了TEVAR时代SAA维修的经验。方法:自2005年美国食品和药物管理局批准TEVAR以来,对在单个机构中修复的所有胸腔内SAA进行了回顾性研究。结果:19例患者接受了20例手术,以修复22例(13例自然,9例异常)胸腔内SAA。零件。 SAA的平均直径为3.1厘米(范围1.6-6.0厘米)。平均患者年龄为57岁(范围24-80岁)。 21%(n = 4)的患者患有结缔组织疾病(两个Loeys-Dietz,两个Marfan)。通过开放技术修复了36%(n = 8)的SAA,通过基于TEVAR的方法修复了64%(n = 14)。所有TEVAR病例都需要在主动脉弓近端着陆区(0-2区),并且83%(10/12)的患者至少需要重新造血管。 50%(n = 10)的手术同时进行了相关的主动脉病理修复。三十天/医院内的死亡率,中风和永久性截瘫/轻瘫的比率分别为5%(n = 1),5%(n = 1)和0%。经过24(21)个月的平均随访(标准差),有16%(n = 3)的患者需要再次行锁骨下动脉旁路移植术翻修(n = 2)或II型内漏(n = 1)。结论:这是迄今为止TEVAR用于SAA修复的最大的单一机构系列。现代血管内技术扩大了SAA修复的选择范围,并取得了优异的效果。现在,可以使用基于TEVAR的方法修复大多数SAA和几乎所有异常的SAA(Kommerell憩室),而无需进行胸骨切开术或开胸术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号